Company Overview and News
NEW YORK, Sept 19 (LPC) - Tetragon Credit Income Partners has hired Scott Snell, the former co-head of BlackRock’s US Collateralized Loan Obligation (CLO) business, as it considers new investments.
JACKSONVILLE, Fla., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Stein Mart, Inc. (NASDAQ: SMRT) (the “Company”) announced today that it has extended and amended its existing revolving credit agreement with Wells Fargo Bank (Wells Fargo) and its term loan agreement with Gordon Brothers Finance Company (GBF). These agreements are coordinated through an intercreditor agreement and provide for combined borrowing availability of $275 million.
WFC WFCNP SMRT
A decade ago, the US was enduring a brutal financial crisis. Many still have memories are bankruptcies, massive losses, home foreclosures, reckless insurers, CDS (credit default swaps) bets and billion-dollar bank bailouts. With the 10-yr anniversary of Lehman Brothers bankruptcy just occurring, most investors remember the losses and pain of the financial crisis. While we learned much from enduring this time-period, as well as the dot-com bust, we thought we would spend some time reviewing a winner from this environment.
WFCNP MGR EV FII BEN MS WFC STT AMG LMHA LMHB BLK LM
NEW YORK, Sept 18 (LPC) - The US$9.25bn in term loans backing private equity firm Blackstone Group’s purchase of a 55% stake in Refinitiv, Thomson Reuters’ Financial and Risk (F&R) division, allocated and broke for trading on Tuesday.
WFCNP BGX DB BGLF MS WFC BX BGB
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), IBM (IBM) and Texas Instruments (TXN). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFCNP SOJA LMT TXN GAS WMT CME WFC SO 7018 URI OXY
VALCOURT, Québec, 18 sept. 2018 (GLOBE NEWSWIRE) -- BRP inc. (TSX : DOO; NASDAQ : DOOO) (« BRP » ou la « Société ») a annoncé aujourd’hui la clôture de son reclassement déjà annoncé visant 8 700 000 actions à droit de vote subalterne vendues par certains de ses actionnaires, dont Beaudier Inc. et 4338618 Canada Inc. (collectivement, le « groupe Beaudier ») ainsi que Bain Capital (« Bain »), au prix d’offre de 47,00 $ US par action, pour un produit brut total revenant aux actionnaires vendeurs de 408 900 000 $ US.
WFC WFCNP MS
2018-09-18 investorplace - 1
U.S. equities opened lower on Monday, led by weakness in high-profile technology stocks and the U.S. dollar. Investors remained concerned about the likelihood of additional trade tariffs against China on reports President Trump is getting ready to unveil another package of taxes on $200 billion worth of imports.
WFC WFCNP FB GOOG GS GOOGL TWTR DIS MCD
Wells Fargo analyst Bonnie Herzog called the news "an exciting potential development" as it would take Coke into another fast-growing healthier segment following last month's $5.1 billion deal for Costa Coffee and expand cannabis-infused drinks in the area of functional wellness products.
Spotify (SPOT) is a Swedish on-demand music streaming giant with the world at its feet. After all, after first bursting onto the scene in 2008, Spotify now rules the industry across the globe.
WFC WFCNP P
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET